Multi-targeting antibiotics, i.e. single compounds capable to inhibit two or more bacterial targets offer a promising therapeutic strategy, but information on resistance evolution against such drugs is scarce.
Introduction
Antibiotic discovery has been driven by the need for new therapeutics that are not subject to rapid resistance development. Antibiotics selectively inhibit bacteria by targeting essential cellular processes which are absent in the human host. Most antibiotics exert their therapeutic effect by targeting a single bacterial process, and therefore they are prone to resistance development resulting from genomic mutations or the acquisition of horizontally transferred resistance genes 1 . Due to the rise of drug-resistant bacteria, the commercial success of antibiotic development is unpredictable 2, 3 .
For example, GlaxoSmithKline (GSK) had been focusing on the development of a novel compound (GSK2251052) that solely inhibits bacterial leucyl-tRNA synthetase. However, the clinical development of this compound was ceased, because resistance induced by mutations emerged in patients treated by GSK2251052 in its Phase 2b clinical trial 4, 5 .
Antibiotic combination therapy has long been suggested as a potential strategy to delay resistance evolution 6, 7 . The rationale for this theory is that drugs with different modes of action generally require different mutations in respective target genes to achieve resistance, and the simultaneous acquisition of multiple specific mutations is exceedingly rare. Although successful in many cases, antimicrobial combination therapy suffers from several limitations 1, 8 . First, the efficacy of a combination therapy relies on fine-tuning the concentrations of multiple drugs in vivo, and this endeavor is frequently hampered by the differences in the individual drugs' pharmacokinetic properties. Second, the prerequisite for combination therapy is the lack of mutations providing resistance to both drugs at the same time, i.e., no cross-resistance should exist between the antibiotics applied together. Third, and on a related note, the small number of available antibiotic families limits practical applications.
Multi-target antibiotic strategy is an emerging alternative that can potentially address the aforementioned challenges. There are multiple mechanisms by which antimicrobial compounds may inhibit multiple bacterial targets. In the case of hybrid drugs, two antibiotic pharmacophores with dissimilar targets are covalently linked to form one molecule. Other antibiotic compounds equipotently target two homologous, but functionally non-redundant proteins. Finally, they may target multiple, non-overlapping regions of a single bacterial protein. Currently, designing multi-target antibiotics is a major focus of the pharmaceutical industry, but until now relatively few drugs have been demonstrated to achieve a balanced inhibition of multiple microbial targets. Such exemplary antibiotics include gepotidacin 9 , NBTI 5463 10 , Trius' C3 and C4 11 . However, due to the shortage of indepth resistance studies, our knowledge on the tempo and mode of resistance development against multi-target antibiotics remains limited (but see [12] [13] [14] ).
Gepotidacin (GSK2140944) is an exemplary candidate to study resistance evolution towards multi-targeting antibiotics ( Figure 1A ). Gepotidacin is a novel triazaacenaphthylene antibiotic candidate currently in phase 2b clinical trials 15, 16 and is expected to enter the clinical practice in the upcoming years 17, 18 . The molecule inhibits bacterial DNA gyrase and topoisomerase IV with a novel mode of action. Using a standard frequency-of-resistance test recent studies have failed to identify resistant clones of Neisseria gonorrhoeae and Escherichia coli against this new compound 9, 19 , suggesting that individual mutations cannot provide substantial resistance to gepotidacin. It is especially active against Gram-negative pathogens belonging to the Enterobacteriaceae family, such as Klebsiella pneumoniae. In fact, Carbapenem-resistant K. pneumoniae is resistant to nearly all commercially available antibiotics, and corresponding infections increase steadily, resulting in high rates of morbidity and mortality. According to the WHO, infections caused by multi-drug resistant Klebsiella strains are emerging as a top-ranked challenge in the health-care sector 20 . In this work, we demonstrate that contrary to expectations, resistance to gepotidacin evolves rapidly in K.
pneumoniae, which has potential implications for the future clinical use of this new antibiotic candidate.
Results

Molecular modelling with directed evolution accurately predicts the positions and impact of resistance mutations
Prior studies have demonstrated that gepotidacin selectively inhibits both bacterial DNA gyrase and topoisomerase IV by a unique mechanism 9, 17 , but the exact molecular mechanisms of inhibition have not been thoroughly characterized. Therefore, we first sought to study the exact molecular interactions between gepotidacin and Escherichia coli's DNA gyrase and topoisomerase IV protein complexes, using molecular modelling (see Methods). Molecular dynamics simulations capture the atomic interactions between the drug and the target protein in time. As the X-ray crystal structures of the protein targets of E. coli are not available, we have built homology models of DNA gyrase and topoisomerase IV based on structural templates from Staphylococcus aureus and K. pneumoniae, respectively (see Methods and Supplementary Note 1). Next, we have calculated the possible binding poses of gepotidacin using molecular docking methods. Finally, we have performed 100 ns long molecular dynamics simulations to check the stability of these binding poses, as well as to map the interaction pattern of gepotidacin and surrounding amino acid residues. The analysis has revealed that hydrophobic contacts are engulfing the pyrano-pyridine moiety of gepotidacin and the drug forms one dominant electrostatic interaction with its binding site at each target protein (Supplementary figure S1 and S2). Specifically, our model has predicted that Asp82 in the GyrA subunit of DNA gyrase and the homologous position, Asp79 of the ParC subunit of topoisomerase IV form an intermolecular salt bridge with gepotidacin ( Figure 1B and C, Supplementary Note 2, and Figure S2 ). Therefore, mutations within this binding site are expected to provide resistance to gepotidacin. Indeed, we have provided evidence to support this hypothesis. Previously we subjected the potential target genes to a single round of DIvERGE mutagenesis in E. coli, and next subjected the mutant library to gepotidacin stress, followed by sequencing the resistant isolates 19 . In our current work, the analysis has been repeated in K. pneumoniae using nearly identical experimental settings ( Figure 1D ). The results of the mutagenesis assays are qualitatively the same for the two species: Asp82 within the GyrA subunit and Asp79 of the ParC subunit are found to be mutated in all the resistant clones isolated, and no further mutations have been found ( Supplementary Table S3 ). Moreover, subsequent saturation mutagenesis of the two mutational hot-spots has recapitulated that the combination of these two specific mutations (GyrA D82N, ParC D79N) is responsible for a high-level of resistance to gepotidacin ( Supplementary Table S3 ).
Next, to understand the molecular mechanisms behind resistance, we have computationally modelled the molecular interactions between gepotidacin and asparagine mutants at GyrA Asp82 and ParC Asp79 positions using the Molecular Mechanics/Generalized Born Surface Area (MM-GBSA) 21 method. MM-GBSA has predicted that the observed mutations (GyrA D82N and ParC D79N) weaken the interaction between the target proteins and gepotidacin (ΔΔGB = 5.44±2.92 and 4.43±1.71 kcal/mol for DNA gyrase and topoisomerase IV, respectively, based on three independent simulations). Thus, the combination of DIvERGE mutagenesis assays and molecular dynamics simulations have revealed the putative binding sites for gepotidacin in DNA gyrase and topoisomerase IV protein complexes. Furthermore, the disruption of an indispensable salt bridge between the drug and its two binding sites resulted in high-level resistance in K. pneumoniae. 
Exceptionally strong synergism between resistance-associated mutations
Next, we have studied the individual, as well as the combined effects of these mutations on resistance. For this purpose, the mutations were inserted individually into the genomes of E. coli K-12 MG1655 and K. pneumoniae ATCC 10031. The double-mutants were found to display an over 560and a 2080-fold increase in gepotidacin resistance level compared to the corresponding wild-type strains of E. coli and K. pneumoniae, respectively (Figure 2 , see also 22 ). In contrast, the singlemutants were found to show no considerable changes in resistance level. GyrA D82N has conferred a mere 2-fold increase in resistance level in E. coli, while ParC D79N on its own has induced no measurable resistance. Similar results were seen for K. pneumoniae. These findings are consistent with prior single-step resistance selection studies that failed to recover mutants with significant resistance 9, 19 . replicates; curve shows the average OD600 values at the corresponding drug concentration.
Fitness cost of gepotidacin resistance is limited
The mechanisms underlying antibiotic resistance typically induce a fitness cost in the form of reduced bacterial growth rates 24 . The magnitude of fitness cost determines the long-term stability of antibioticresistant bacterial populations [25] [26] [27] . Thus, we have investigated the fitness effects of target-mediated resistance to gepotidacin in K. pneumoniae. For this aim we have studied the wild-type and mutant K.
pneumoniae strains, the latter carrying gepotidacin or fluoroquinolone resistance-associated mutations.
The fluoroquinolone resistance-causing mutations in point are widespread in clinical isolates [28] [29] [30] and affect the same genes (namely, gyrA and parC), therefore they provide a benchmark to estimate the fitness costs compared to the wild-type strain. Relative fitness was estimated by pairwise competition experiments between the wild-type strain and a specific mutant strain in nutrientrich, antibiotic-free bacterial medium (MHBII) at 37°C. Using established protocols, we have found that the mutation combination of GyrA D82N and ParC D79N which confers resistance to gepotidacin significantly decreases fitness in K. pneumoniae. However, the fitness cost of gepotidacin resistanceassociated mutations is comparable to the fitness cost of canonical, clinically relevant fluoroquinolone resistance-causing mutations. Importantly, ParC D79N mutation is found to confer no measurable fitness cost individually ( Figure 3 ). Our findings remained the same when active human blood serum was added to the medium (see Supplementary Figure S3 ). mutants and the wild-type strain as a function of bacterial generation number. The ratio of genotypes was defined as the ratio of the given mutant compared to the wild-type strain within the cell population. The gray zone indicates 95% confidence interval based on five biological replicates.
Gepotidacin-resistant mutants display no changes in virulence in a murine infection model
Based on the above results, we next investigated whether gepotidacin-resistant mutants display reduced virulence in vivo. As drug-resistant K. pneumoniae is frequently responsible for wound and systemic infections, we have studied a murine thigh wound infection model 31, 32 . Specifically, we have examined the wound colonization capacity of the wild-type strain, as well as that of representative gepotidacin-and ciprofloxacin-resistant K. pneumoniae mutants. For this purpose, the wild-type strain, as well as each isogenic mutant strain was inoculated into the thigh tissue of female ICR mice (n = 5). After 26 hours, bacterial colonization was determined by plating thigh tissue homogenates to MHBII agar plates. No significant decrease in in vivo virulence was observed for any of the resistant mutants compared to the wild-type strain ( Figure 4 ). 
Cross-resistance between gepotidacin and ciprofloxacin
Taken together, the above results demonstrate that the combination of two mutations in the genes encoding gepotidactin's target proteins confer an over 2000-fold increase in gepotidacin-resistance in K. pneumoniae. Alarmingly, these mutations do not seriously affect bacterial fitness and virulence in vivo.
Several prior works demonstrate that certain resistance mutations are present in bacterial populations long before being exposed to an antibiotic in point. Thus, we hypothesized that prolonged use of other antibiotics might select for mutations that serve as stepping-stones towards gepotidacinresistance. The best candidate antibiotic family is fluoroquinolones, as they are widely employed in clinical practice, and similarly to gepotidacin, they target the gyrase/topoisomerase protein complexes, albeit with a notably different molecular mechanism 18, 33 . Moreover, the putative binding sites of gepotidacin and fluoroquinolones on the GyrA protein are adjacent to each other, separated by a single amino acid only (see figure 1B , and [34] [35] [36] ). Despite the functional similarities between these drug classes, a prior paper reported that fluoroquinolone-resistant clinical isolates displayed no crossresistance to gepotidacin 18 . To re-investigate this issue, we have focused on ciprofloxacin, a widely employed and well-characterized fluoroquinolone drug.
We have found that the GyrA D82N single-mutant strain displays an over 16-fold increase in ciprofloxacin-resistance compared to the wild-type K. pneumoniae ATCC 10031 strain. This finding is even more remarkable if we consider that the same mutation confers only a 2-fold increase in the level of resistance to gepotidacin. As it might be expected, the GyrA D82N and ParC D79N doublemutant also displays significant resistance to ciprofloxacin ( Figure 5 ). (Table 1 ) and also in laboratory experiments [45] [46] [47] [48] . In line with this hypothesis, we have demonstrated that the mutation combination of GyrA D82N, existing in clinical isolates, and an additional D79N mutation at ParC causes a more than 128-fold increase in gepotidacin-resistance in S. enterica ( Figure 6 ). These results indicate that several clinically occurring human pathogens require only a single extra mutation to evolve high-level resistance to gepotidacin.
Species
Detected mutations Prevalence (%) Reference
Salmonella enterica
GyrA D82N Streptococcus are especially noteworthy, as infections caused by these genera are reported to be the targets of gepotidacin in recent clinical trials 15, 16, 49 .
Ciprofloxacin stress selects for gepotidacin resistance in the laboratory
To establish that ciprofloxacin promotes gepotidacin resistance, we have initiated laboratory evolution under ciprofloxacin stress. We followed established protocols with minor modifications to evolve bacterial populations under controlled laboratory conditions [50] [51] [52] . The protocol aims to maximize the level of drug resistance in the evolving populations that develop in a fixed time period, being approximately 116 generations in our case. For our laboratory evolutionary experiments, we have chosen the wild-type K. pneumoniae ATCC 10031, as well as the wild-type and mutS variants of E.
coli K-12 MG1655. Six parallel evolving populations of every strain were exposed to gradually increasing concentrations of ciprofloxacin. mutS displays around 100-fold increase in mutation rate, and as being a hypermutator, it adapts especially rapidly to various antibiotic stresses. In line with previous clinical and laboratory studies 33, 53 , ciprofloxacin resistance was seen to emerge quickly in our experiments ( Figure 7) . Despite the short time-frame, all E. coli and K. pneumoniae populations reached ciprofloxacin-resistance levels equal to or above the EUCAST clinical breakpoint 54 (Figure 7 ).
As expected, the evolution of clinically significant resistance was especially rapid in mutator populations.
Strikingly, ciprofloxacin-resistant lineages of both species have been found to display an over 64 to 512-fold increment in gepotidacin-resistance level compared to the corresponding wild-type strains ( Figure 8 ). Some, but not all of these gepotidacin-resistant lineages carried mutations at GyrA D82 and ParC D79 ( Supplementary Table S2 ), suggesting that multiple other mutations may also select for gepotidacin resistance. Overall, these results strongly suggest that long-term exposure to ciprofloxacin stress promotes resistance to gepotidacin. Supplementary Table S2 .
Discussion
Gepotidacin is a novel bacterial topoisomerase inhibitor (NBTI) antibiotic candidate that simultaneously inhibits both bacterial gyrase and topoisomerase IV with a novel mechanism of action.
Therefore, it is an excellent candidate to study the evolution of resistance against dual-targeting antimicrobials. As it is still under clinical development, it is highly relevant to predict the tempo and mechanisms of resistance development against this new drug candidate.
As a good benchmark for mono-targeting drugs, both mutation rate and population size should be high enough to test at least three mutations across 99.9% of nucleotide sites in the genome, requiring that 2×10 11 wild-type cells are assayed is in a frequency-of-resistance assay 50 . For multi-targeting drugs, this mutational space scales exponentially with the number of targets. Thus, for a drug with two bacterial targets, screening over 10 22 wild-type E. coli cells would be required to identify mutation combinations that may confer resistance. Strains with an elevated genomic mutation rate (hypermutators) could potentially reduce this astronomical number, but testing over 10 18 mutator bacteria still remains infeasible 55, 56 . Recent genome-engineering technologies, however, offer promising alternatives to explore resistance-conferring mutations in a more systematic manner 19, [57] [58] [59] [60] .
One of these methods termed directed evolution with random genomic mutations (DIvERGE) 19 allows an up-to a million-fold increase in mutation rate along the full length of bacterial genes encoding drug targets. Thus, it is capable to rapidly explore specific mutational combinations that confer resistance to antibiotics.
Using DIvERGE, we have primarily focused on studying the evolution of resistance to gepotidacin in Klebsiella pneumoniae ( Figure 1D ). Currently, the rise of drug-resistant Klebsiella infections is especially alarming, as this pathogen is frequently responsible for life-threatening diseases, including pneumonia, sepsis and wound infections. Isolates that are resistant to all marketed antibiotics have already been detected 28 . As gepotidacin shows excellent potency against Gram-negative bacteria 17, 18, 61 , it could offer a last resort drug to treat multidrug-resistant Klebsiella infections.
However, we have demonstrated that two specific mutations in the genes encoding gepotidacin's targets can provide a very high level of resistance in multiple enterobacterial species 22 (see also Figure 2 According to what we term the "stepping-stone" hypothesis, prolonged clinical deployment of certain antibiotics may select for variants with an elevated potential to evolve resistance to new antimicrobial agents. For example, in Staphylococcus aureus the genetic alteration responsible for methicillin-resistance had emerged due to the selective pressure of first-generation beta-lactams, such as penicillin, years before methicillin was first applied in clinical practice 62 . Furthermore, the byproducts of drug degradation were also shown to promote resistance development against clinically applied antibacterials 63 .
To investigate the feasibility of the "stepping-stone" hypothesis, here we have focused on ciprofloxacin, a widely employed and well-characterized fluoroquinolone antibiotic 64 The "stepping-stone" hypothesis may have general implications. For example, zoliflodacin (ETX0914), a novel bacterial topoisomerase inhibitor has just completed a human phase 2 clinical trial 65 . It shows promising activity against multidrug-resistant infections, including N. gonorrhoeae 66 .
However, in this species mutations in GyrB have been reported to confer zoliflodacin-resistance 67 , and one of these zoliflodacin-resistant mutants (D429N) has already been detected in clinical populations 68 . As the homologous GyrB mutation (D426N) in E. coli confers resistance to fluoroquinolones 22 , fluoroquinolone agents might have incidentally selected for reduced susceptibility to zoliflodacin as well. Consistent with this hypothesis, naturally occurring zoliflodacin-resistant variants were also found to be highly resistant to fluoroquinolones 68 .
In summary, our work demonstrates that despite a balanced in vivo targeting of multiple proteins, high-level resistance can rapidly emerge to antibiotics when the drug molecule's inhibitory effect depends merely on interactions with a few, indispensable amino acids. Moreover, based on adaptive laboratory evolution and clinical data, we propose that target gene mutations conferring resistance to fluoroquinolones can facilitate resistance evolution to novel topoisomerase-targeting antimicrobials, including gepotidacin. Therefore, existing resistant bacteria could serve as an immediate source of novel resistance mechanisms.
As a more general concept, our work indicates that even drugs executing a balanced multi-targeting of bacterial proteins are prone to resistance, and multi-targeting itself does not preclude the appearance of high-level resistance to antimicrobials. Regarding that a quarter of the antibiotics currently under clinical development target bacterial topoisomerases 69 , further research is warranted to test this scenario.
Supplementary Information
Supplementary Note 1. Homology model construction for E. coli DNA gyrase and topoisomerase IV. To construct homology models of E. coli DNA gyrase and topoisomerase IV, homologous bacterial protein sequences were downloaded from UniProt (https://www.uniprot.org/) (see also Methods). Sequence alignments were carried out using the Schrödinger Program Suite 70 with BLOSUM62 substitution matrix, with -10.0 as gap opening and -1.0 as gap extension penalty.
Supplementary Table S1
lists sequence identities and homologies of target-template sequence pairs used in our homology model construction.
Target-template pairs Identity (%) Homology (%)
GyrA P0AES4-P20831 50 69
GyrB P0AES6-P0A0K8 44 56
ParC P0AFI2-R4YE07 95 97
ParE P20083-R4YHS8 94 97 Supplementary Table S1 . 
Materials and Methods
Media and antibiotics
For general growth of bacteria and electrocompetent cell preparation, Lysogeny-Broth-Lennox (LB), medium was used (10 g tryptone, 5 g yeast extract, 5 g sodium chloride per 1 l of water). For cell recovery after electroporation, we applied Terrific Broth (TB) (24 g yeast extract, 12 g tryptone, 9.4 g K2HPO4, and 2 g KH2PO4 per 1 l of water). For antimicrobial susceptibility tests and the selection of 
Computational docking of gepotidacin
We docked gepotidacin (ChemSpider ID: 34982930) into the DNA gyrase and topoisomerase IV homology models using Glide from the Schrödinger package 70 . The protonation state of gepotidacin was selected as the main species obtained from pKa calculation using the calculator plugin of Marvin program 71 . For Glide docking we used OPLS3 force field 72 and the standard precision procedure with flexible ligand geometries and enhanced conformational sampling. Based on the high similarity of the mode-of-action of GSK945237 and gepotidacin 61 , we picked the docking pose of gepotidacin that was most similar to the binding pose of GSK945237 in 5NPP structure. This procedure was repeated for the other docking-pose of GSK945237, as well. Finally, the binding site (defined as residues closer than 5 Å to the ligand) geometry together with the docked ligand was optimized. We followed the same steps in the case of both homology models.
Molecular dynamics simulations of gepotidacin bound DNA-gyrase and DNA-topoisomerase IV complexes
To perform molecular dynamics-based binding mode analysis for gepotidacin at both of its targets, we first parametrized the complex of formed by gepotidacin-DNA-and its corresponding target (DNA gyrase and topoisomerase IV, respectively). For parametrization, we used OPLS3 force field 72 . Next, this system was solvated using the SPC (simple point charge) explicit water model 73 within an orthorhombic box 10 Å apart. On the course of simulations, NaCl in 0.15 M final concentration was used to mimic the physiological conditions. 100 ns molecular dynamics calculations were carried out on these systems at constant volume and temperature (NVT) using the Desmond molecular dynamics code 79 . Snapshots of these simulations were used as a conformational ensemble in mutation-induced binding free energy change calculations.
Estimation of mutation-induced binding free energy changes
Asparagine-mutation induced changes of the binding affinity (ΔΔGB) of gepotidacin at GyrA D82, and
ParC D79 positions were calculated as the difference of their binding free energy in the mutated and wild-type enzyme (ΔΔGB= ΔGB MUT -ΔGB WT ). This affinity change was estimated by using Residue Scanning module of Bioluminate package 75 and was based on molecular mechanics-generalized Born surface area (MM-GBSA) approximation 21 . Specifically, we estimated the binding free energy of a ligand (∆ ) by using the single trajectory approach 76 in which a single molecular dynamics simulation of the protein-ligand complex is completed first and sample geometries are collected from the trajectory to represent the possible binding conformations. ∆ is calculated for every single geometry
where , and are the energy of the protein ligand complex, protein and ligand, respectively.
These energy values are calculated as
where is the calculated molecular mechanics energy for the force field applied, and is the solvation energy in the generalized Born approximation. Different variations of this method are widely used in large scale drug design studies [81] [82] [83] as it accurately predicts mutational effects in drug-protein interaction analyses with a manageable computational demand (see e.g. references 80, 81 ). In our study, MM-GBSA calculations were carried out with the thermal_mmgbsa.py script Schrödinger package 75 from 100, evenly spaced structures from the second 50 ns of our previously performed moleculardynamics simulation between the wild-type enzyme (DNA gyrase and topoisomerase IV) and
gepotidacin.
Plasmid construction
To perform ssDNA recombineering and DIvERGE in K. pneumoniae ATCC 10031, we generated a 
DIvERGE in Klebsiella pneumoniae
DIvERGE in Klebsiella pneumoniae ATCC 10031 was carried out according to a previously described DIvERGE workflow 22 , with minor modifications. Briefly, K. pneuomoniae cells carrying pORTMAGE311B plasmid were inoculated into 2 ml LB medium + 50 μg/ml kanamycin and were grown at 37 °C, 250 rpm overnight. From this starter culture, 500 µl stationary phase culture was inoculated into 50 ml LB medium + 50 μg/ml kanamycin, and grown at 37 °C under continuous shaking at 250 rpm. Induction was initiated at OD600 = 0.4 by adding 50 μl 1 M m-Toluic-acid (Sigma-Aldrich, dissolved in 96% ethyl-alcohol). Induction was performed for 30 minutes at 37 °C. After induction, cells were cooled on ice for 15 minutes. Next, cells were washed 3-times with 50 ml sterile, ice-cold, ultra-pure distilled water. Finally, the cell pellet was resuspended in 800 μl sterile ultra-pure distilled water and kept on ice until electroporation.
To perform DIvERGE, and separately, the saturation mutagenesis of GyrA D82 and ParC D79, the corresponding gyrA, and parC-targeting oligos were equimolarly mixed at a final concentration of 500 μM and 2 μl of this oligo-mixture was added to 40 µl electrocompetent cell in 10 parallels. Following the electroporation of each sample, the 10 parallel samples were pooled together, and immediately after electroporation cells were suspended in 50 ml TB to allow for cell recovery. After a 1-hour recovery period at 37 °C, 250 rpm, an additional 50 ml LB medium along with 50 μg/ml (final cc.) kanamycin was added. Next, cells were grown at 37 °C, 250 rpm for 24 hours. To select gepotidacin resistant clones from this DIvERGE library, 500 µl cell library was spread to 6 µg/ml gepotidacincontaining MHBII agar plates and plates were incubated at 37 °C for 48 hours. Finally, 10 randomly selected colonies were analyzed by capillary sequencing (oligos: KPGA1F, KPGA1R and KPPC1F, KPPC1R) from both antibiotic-selected cell libraries.
Engineering gepotidacin resistance-associated mutations in Escherichia coli
To assess the phenotype of gepotidacin resistance-associated mutations, we individually reconstructed both GyrA D82N and ParC D79N mutations in E. coli K-12 MG1655. We utilized a previously described CRISPR-MAGE protocol to integrate mutations and counter select against the wild-type genotype 83, 84 . Briefly, cell-containing pORTMAGE2 (Addgene #72677) were transformed with pCas9 (Addgene #42876) and were grown in LB + 100 µg/ml ampicillin + 20 µg/ml chloramphenicol broth at 30 o C. Next, pCRISPR plasmids (Addgene #42875) were constructed with crRNA sequences targeting the wild-type gyrA and parC loci in the vicinity of D82 and D79 according to a previously described protocol (oligos: ECGACRF1, ECGACRR1, and ECPCCRF1, ECPCCRR1, respectively). Following plasmid-construction, correct clones were identified by capillary sequencing. Next, mutants were selected on MHBII + 6 μg/ml gepotidacin agar plates at 37 °C. Finally, the presence of the two mutations was identified and validated by capillary sequencing using SEGAF1, SEGAR1, and SEPCF1, SEPCR1 oligos.
Adaptive laboratory evolution of ciprofloxacin resistance
Adaptive laboratory evolution experiments followed an established protocol for automated laboratory evolution 85 ensure an optimal oxygen exchange rate and limit evaporation and were shaken at 150 rpm at 37 ˚C.
Twenty μl of each evolving culture was parallelly transferred into four independent wells containing 350 μl fresh medium and an increasing concentration of gepotidacin and ciprofloxacin (i.e., 0.5×, 1×, 
In vitro growth-rate measurements
We measured the growth phenotype of bacterial variants by assessing their growth at 37 C in MHBII medium. To measure growth, we inoculated 5×10 4 cells from early stationary phase cultures (prepared in MHBII medium) into 100 μl of MHBII medium in a 96 well microtiter plate and monitored growth for 24 h. Bacterial growth was measure as the 600 nm optical density (OD600) of cultures at a given timepoint. OD600 measurements were carried out every 5 minutes using BioTek Synergy 2 microplate reader while bacterial cultures were grown at 37 C under continuous, variable intensity shaking. Each bacterial variant and their corresponding wild-types were measured in two consecutive experiments, with 12 replicates in each subsequent tests (24 biological replicates in total). Finally, growth rates were calculated from the obtained growth curves according to a previously described procedure 86, 87 .
Competition-based fitness measurements
Competition assay-based fitness measurements were carried out by competing mutant strains against their corresponding wild-type strain carrying a lacZ knockout mutation. The lacZ knockout strain was constructed by integrating a premature stop codon in place the 23 rd amino acid of LacZ with a previously reported pORTMAGE protocol 60 Competition experiments were performed in five replicates. Finally, selection coefficients were estimated as the slope of the change in ratio, as defined in the following equation where s is the selection coefficient, t is time or number of generations, x1 and x2 are the ratio of the two strains at a given time point 88 . 
Prevalence of gepotidacin resistance-associated mutations in sequence databases
Mouse thigh infection models
Drug-resistant K. pneumoniae is frequently responsible for wound and systemic infections, therefore, we benchmarked in vivo effects of gepotidacin resistance in a murine thigh wound infection model 31, 32 .
Specifically, we examined wound colonization for representative gepotidacin and ciprofloxacinresistant mutants of K. pneumoniae ATCC 10031 and compared to that of the wild-type. Murine thigh infections were performed according to a previously established protocol 32, 90 . Bacterial inoculums were prepared by inoculating single bacterial colonies into 5 ml of MHBII broth and were incubated at 37 °C for 16 hours under constant agitation (250 rpm). Next, ½ volume of 50 volume/volume% glycerol:water mixture was added to each culture and 550 µl of these cell suspensions were frozen at -80 °C. Before inoculation, cell suspensions were allowed to thaw at room temperature for 15 minutes. As test animals, groups of 5 female specific-pathogen-free ICR (CD-1) mice weighing 22 ± 2 g were used. Animals were immunosuppressed by two intraperitoneal injections of cyclophosphamide, the first at 150 mg/kg 4 days before infection (day -4) and the second at 100 mg/kg 1 day before infection (day -1). On day 0, animals were inoculated intramuscularly into the right thigh with 10 6 CFU/mouse of the corresponding pathogenic mutant (0.1 ml culture/thigh). After 26 hours inoculation, animals were humanely euthanized with CO2 asphyxiation and then the muscle of the right thigh was harvested from each test animal. The removed muscle was homogenized in 3 ml of phosphate-buffered saline, pH 7.4, with a polytron homogenizer. Finally, 0.1 mls of these homogenates were used for serial 10-fold dilutions and plated onto LB agar for colony count (CFU/g) determination.
All aspects of this work including housing, experimentation, and animal disposal were 
Minimum Inhibitory Concentration measurements
Minimum Inhibitory Concentrations (MICs) were determined using a standard serial broth microdilution technique according to the EUCAST guidelines 23 (ISO 20776-1:2006, Part 1). Briefly, bacterial strains were inoculated from frozen cultures onto MHBII agar plates and were grown overnight at 37 °C. Next, independent colonies from each strain were inoculated into 1 ml MHBII medium and were propagated at 37 °C, 250 rpm overnight. To perform MIC assays, 12-step serial dilutions using 2-fold dilution-steps of the given antibiotic were generated in 96-well microtiter plates (Sarstedt 96-well microtest plate with lid, flat base). Antibiotics were diluted in 100 μl of MHBII medium. Following dilutions, each well was seeded with an inoculum of 5×10 4 bacterial cells. Each measurement were performed at least in 3 parallel replicates. Also, to avoid possible edge effects at the edge of the microwell plate, side-rows (A and H) contained only medium without bacterial cells.
Following inoculations, plates were covered with lids and wrapped in polyethylene plastic bags to minimize evaporation but allow for aerobic O2 transfer. Plates were incubated at 37 °C under continuous shaking at 150 rpm for 18 hours in an INFORS HT shaker. After incubation, OD600 of each well on the microwell plate was measured using a Biotek Synergy 2 microplate reader. MIC was defined as the antibiotic concentration which inhibited the growth of the bacterial culture, i.e., the drug concentration where the average OD600 increment of the three replicates was below 0.05.
